Finding 480860 (2021-006)

Significant Deficiency Repeat Finding
Requirement
M
Questioned Costs
-
Year
2021
Accepted
2024-08-09

AI Summary

  • Core Issue: AAPT did not document pre-award risk assessments for subrecipients, violating 2 CFR 200.331 requirements.
  • Impacted Requirements: Lack of risk evaluation may lead to oversight gaps, allowing higher-risk subrecipients to operate without proper monitoring.
  • Recommended Follow-Up: AAPT should adhere to internal policies, document risk assessments, and implement a risk scaling system to guide oversight procedures.

Finding Text

Finding 2021-006: Subrecipient Monitoring Federal Programs: Research and Development Cluster: 47.076 - STEM +C Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): As stated in 2 CFR 200.331 part (b), all pass-through entities must evaluate each subrecipient's risk of noncompliance with Federal statutes, regulations, and the terms and conditions of the subaward for purposes of determining the appropriate subrecipient monitoring procedures to prescribe to each individual subrecipient. Condition: During our audit work over subrecipient monitoring, we were unable to verify that pre-award risk assessment procedures were performed. It is our understanding that AAPT has ongoing relationships with these subrecipients and evaluation of these subrecipients' risk is a continual process; however, these procedures were not documented. Cause: AAPT’s internal policies and procedures governing risk assessment on subrecipient was not performed. Effect or Potential Effect: AAPT could inadvertently engage in relationships with subrecipients of higher risk without the appropriate level of oversight to ensure subrecipients are expending funds in accordance with the provisions and terms of the subaward. Questioned Costs: None noted. Context: Our audit procedures consisted of examining documentation of the subrecipient monitoring process, and evaluating internal controls over the process. Identification as a Repeat Finding, if Applicable: 2020-006. Recommendation: We recommend AAPT follow their internal policies and procedures surrounding subrecipients and document the risk assessment criteria for the purpose of determining the expected level of oversight during the period of performance. This evaluation should include a scaling system, such as high, medium or low risk (for example), and the monitoring tools and procedures to be performed at each of these levels (additional training, on-site reviews, types of and frequency of reporting, etc.). Views of Responsible Officials and Planned Corrective Actions: Management will continue to perform risk assessment procedures and will thoroughly document the processes and evaluations. Anticipated Completion Date: 12/31/2022 Responsible Official: Michael Brosnan, CFO

Corrective Action Plan

Finding 2021-006: Subrecipient Monitoring Federal Programs: Research and Development Cluster: Stem +C Cause: AAPT's internal policies and procedures governing risk assessment on subrecipient was not performed. Views of Responsible Officials and Planned Corrective Actions: Management will continue to perform risk assessment procedures and will thoroughly document the processes and evaluations. Anticipated Completion Date: December 17, 2021 Responsible Official: Michael Brosnan CFO

Categories

Subrecipient Monitoring Period of Performance

Other Findings in this Audit

  • 480849 2021-003
    Material Weakness Repeat
  • 480850 2021-005
    Significant Deficiency Repeat
  • 480851 2021-003
    Material Weakness Repeat
  • 480852 2021-005
    Significant Deficiency Repeat
  • 480853 2021-003
    Material Weakness Repeat
  • 480854 2021-005
    Significant Deficiency Repeat
  • 480855 2021-003
    Material Weakness Repeat
  • 480856 2021-004
    Significant Deficiency Repeat
  • 480857 2021-005
    Significant Deficiency Repeat
  • 480858 2021-003
    Material Weakness Repeat
  • 480859 2021-005
    Significant Deficiency Repeat
  • 480861 2021-003
    Material Weakness Repeat
  • 480862 2021-005
    Significant Deficiency Repeat
  • 480863 2021-003
    Material Weakness Repeat
  • 480864 2021-004
    Significant Deficiency Repeat
  • 480865 2021-005
    Significant Deficiency Repeat
  • 480866 2021-003
    Material Weakness Repeat
  • 480867 2021-005
    Significant Deficiency Repeat
  • 480868 2021-003
    Material Weakness Repeat
  • 480869 2021-005
    Significant Deficiency Repeat
  • 480870 2021-003
    Material Weakness Repeat
  • 480871 2021-005
    Significant Deficiency Repeat
  • 480872 2021-003
    Material Weakness Repeat
  • 480873 2021-005
    Significant Deficiency Repeat
  • 480874 2021-003
    Material Weakness Repeat
  • 480875 2021-005
    Significant Deficiency Repeat
  • 480876 2021-003
    Material Weakness Repeat
  • 480877 2021-005
    Significant Deficiency Repeat
  • 480878 2021-005
    Significant Deficiency Repeat
  • 480879 2021-005
    Significant Deficiency Repeat
  • 480880 2021-003
    Material Weakness Repeat
  • 480881 2021-005
    Significant Deficiency Repeat
  • 480882 2021-005
    Significant Deficiency Repeat
  • 1057291 2021-003
    Material Weakness Repeat
  • 1057292 2021-005
    Significant Deficiency Repeat
  • 1057293 2021-003
    Material Weakness Repeat
  • 1057294 2021-005
    Significant Deficiency Repeat
  • 1057295 2021-003
    Material Weakness Repeat
  • 1057296 2021-005
    Significant Deficiency Repeat
  • 1057297 2021-003
    Material Weakness Repeat
  • 1057298 2021-004
    Significant Deficiency Repeat
  • 1057299 2021-005
    Significant Deficiency Repeat
  • 1057300 2021-003
    Material Weakness Repeat
  • 1057301 2021-005
    Significant Deficiency Repeat
  • 1057302 2021-006
    Significant Deficiency Repeat
  • 1057303 2021-003
    Material Weakness Repeat
  • 1057304 2021-005
    Significant Deficiency Repeat
  • 1057305 2021-003
    Material Weakness Repeat
  • 1057306 2021-004
    Significant Deficiency Repeat
  • 1057307 2021-005
    Significant Deficiency Repeat
  • 1057308 2021-003
    Material Weakness Repeat
  • 1057309 2021-005
    Significant Deficiency Repeat
  • 1057310 2021-003
    Material Weakness Repeat
  • 1057311 2021-005
    Significant Deficiency Repeat
  • 1057312 2021-003
    Material Weakness Repeat
  • 1057313 2021-005
    Significant Deficiency Repeat
  • 1057314 2021-003
    Material Weakness Repeat
  • 1057315 2021-005
    Significant Deficiency Repeat
  • 1057316 2021-003
    Material Weakness Repeat
  • 1057317 2021-005
    Significant Deficiency Repeat
  • 1057318 2021-003
    Material Weakness Repeat
  • 1057319 2021-005
    Significant Deficiency Repeat
  • 1057320 2021-005
    Significant Deficiency Repeat
  • 1057321 2021-005
    Significant Deficiency Repeat
  • 1057322 2021-003
    Material Weakness Repeat
  • 1057323 2021-005
    Significant Deficiency Repeat
  • 1057324 2021-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
43.001 Science $41,592
47.049 Mathematical and Physical Sciences $23,501
47.076 Education and Human Resources $20,896